Versant Venture Capital VI, L.P. 13D and 13G filings for Aligos Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-08 5:44 pm Unchanged |
2023-11-02 | 13D | Aligos Therapeutics, Inc. ALGS |
Versant Venture Capital VI, L.P. | 58,317 1.900% |
0 (Unchanged) |
Filing |
| 2021-06-21 4:44 pm Sale |
2021-06-11 | 13D | Aligos Therapeutics, Inc. ALGS |
Versant Venture Capital VI, L.P. | 58,317 3.800% |
-19,439 (-25.00%) |
Filing |
| 2021-05-03 4:57 pm Sale |
2021-04-26 | 13D | Aligos Therapeutics, Inc. ALGS |
Versant Venture Capital VI, L.P. | 77,757 5.100% |
-19,439 (-20.00%) |
Filing |
| 2020-10-30 4:25 pm Purchase |
2020-10-20 | 13D | Aligos Therapeutics, Inc. ALGS |
Versant Venture Capital VI, L.P. | 97,196 7.200% |
97,196 (New Position) |
Filing |